| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-04-03 | Glassia® (liquid form of human Alpha-1 Antitrypsin (AAT) administered intravenously) | graft-versus-host disease (GVHD) | 1-2 | Kamada (Israel) Baxter (USA - IL) | Transplantation |
| 2014-04-03 | recombinant human Nerve Growth Factor (rhNGF) | retinitis pigmentosa |
1-2 | Dompé (Italy) | Ophtalmological diseases - Rare diseases |
| 2014-04-02 | MAGE-A3 antigen-specific cancer immunotherapeutic | non-small cell lung cancer patients | 3 | GSK (UK) | Cancer - Oncology |
| 2014-04-02 | combination of Xofigo® (radium-223 dichloride), Zytiga® (abiraterone) and prednisone/prednisolone | treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer (CRPC) |
3 | Bayer HealthCare (Germany) Janssen Research and Development - J&J (USA - NJ) | Cancer - Oncology |
| 2014-04-02 | CetuGEX™ ( anti-epidermal growth factor receptor (EGFR) monoclonal antibody) | squamous cell carcinomas of the head and neck (SCCHN) | 2b | Glycotope (Germany) | Cancer - Oncology |
| 2014-04-02 | SYD985 (HER2-targeting antibody-drug conjugate based on trastuzumab and Synthon’s proprietary cleavable linker-duocarmycin (vc-seco-DUBA) payload) | breast cancer | preclinical | Synthon (The Netherlands) | Cancer - Oncology |
| 2014-04-01 | alirocumab (SAR236553/REGN727) | patients with primary hypercholesterolemia with elevated LDL-C | 2 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases |
| 2014-04-01 | Votrient® (pazopanib) | advanced renal cell carcinoma | 3 | GSK (UK) | Cancer - Oncology |
| 2014-03-31 | cariprazine | bipolar depression | 2b | Forest Laboratories (USA) Gedeon Richter (Hungary) | CNS diseases |
| 2014-03-31 | volanesorsen (ISIS-APOCIIIRx) | patients with high to severely high triglycerides on stable doses of fibrates |
2 | Isis Pharmaceuticals (USA - CA) | Cardiovascular diseases - Metabolic diseases |
| 2014-03-31 | ETS2101 (dexanabinol) | advanced solid tumours |
1 | e-Therapeutics (UK) | Cancer - Oncology |
| 2014-03-31 | AM-101 | acute inner ear tinnitus | 2b | Auris Medical (Switzerland) | Otorhinolaryngology |
| 2014-03-30 | darapladib | reduction of cardiovascular events in patients with coronary heart disease |
3 | GSK (UK) | Cardiovascular diseases |
| 2014-03-30 | evolocumab (AMG 145) | patients with high cholesterol who cannot tolerate statins | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2014-03-29 | evolocumab (AMG 145) | patients with high cholesterol on risk-based lipid-lowering therapy | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2014-03-29 | evolocumab (AMG 145) | patients with hyperlipidemia at risk for cardiovascular disease | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2014-03-28 | NVP018 | hepatitis B | NeuroVive Pharmaceutical (Sweden) | Infectious diseases | |
| 2014-03-28 | momelotinib | metastatic pancreatic ductal adenocarcinoma | 3 | Gilead Sciences (USA - CA) | Cancer - Oncology |
| 2014-03-27 | Pergoveris® (follitropin alfa and lutropin alfa) | Assisted Reproductive Technology (ART) treatment cycle in women who are classified as poor ovarian responders | 3 | Merck KGaA (Germany) | Gynecology - Women\'s health |
| 2014-03-27 | indatuximab ravtansine (BT-062) | triple-negative metastatic breast cancer or metastatic urinary bladder cancer expressing the receptor CD138 | 1-2a | Biotest (Germany) | Cancer - Oncology |
